Patient and graft characteristics of dCBT recipients (n = 90)
| Variables . | Value . |
|---|---|
| Patient characteristics | |
| Age, median (range), y | 47 (21-63) |
| Weight, median (range), kg | 80 (47-138) |
| Sex, male, n (%) | 47 (52) |
| Ancestry, non-European, n (%) | 49 (54) |
| CMV seropositive, n (%) | 55 (61) |
| Diagnosis and disease status, n or n (%) | |
| Acute leukemia | 61 (68) |
| CR1 | 46 |
| CR2 | 11 |
| Relapsed/refractory | 4 |
| MDS | 8 (9) |
| <5% blasts | 4 |
| ≥5% blasts | 4 |
| CML | 3 (3) |
| Chronic phase | 2 |
| Accelerated phase | 1 |
| MPD | 3 (3) |
| <5% blasts | 2 |
| ≥5% blasts | 1 |
| NHL | 14 (16) |
| Large cell B cell | 2 (2) |
| CR | 1 |
| PR | 1 |
| Low-grade B-cell | 3 (3) |
| CR | 2 |
| PR | 1 |
| T cell | 9 (10) |
| CR | 4 |
| PR | 4 |
| Progressive disease | 1 |
| Blastic plasmacytoid dendritic cell neoplasm | 1 (1) |
| CR | 1 |
| HCT-CI, n (%) | |
| 0 | 18 (20) |
| 1-2 | 40 (44) |
| 3-4 | 26 (29) |
| 5-8 | 6 (7) |
| Median (range) | 2 (0-8) |
| rDRI, n (%) | |
| Low | 6 (7) |
| Intermediate | 62 (69) |
| High | 21 (23) |
| Very high | 1 (1) |
| Graft characteristics (n = 180 units)* | |
| Infused TNC dose, median (range), × 107/kg per unit | 2.5 (1.0-7.4) |
| Infused viable CD34+ dose, median (range), × 105/kg per unit | 1.3 (0.2-8.3) |
| Unit recipient HLA- A, -B antigen, -DR allele match, n (%) | |
| 4/6 | 162 (90) |
| 5/6 | 16 (9) |
| 6/6 | 2 (1) |
| Unit recipient 8-allele HLA-match, n (%) | |
| 3-4/8 | 80 (44) |
| 5/8 | 76 (42) |
| 6-7/8 | 24 (13) |
| Median (range) | 5/8 (3-7/8) |
| Variables . | Value . |
|---|---|
| Patient characteristics | |
| Age, median (range), y | 47 (21-63) |
| Weight, median (range), kg | 80 (47-138) |
| Sex, male, n (%) | 47 (52) |
| Ancestry, non-European, n (%) | 49 (54) |
| CMV seropositive, n (%) | 55 (61) |
| Diagnosis and disease status, n or n (%) | |
| Acute leukemia | 61 (68) |
| CR1 | 46 |
| CR2 | 11 |
| Relapsed/refractory | 4 |
| MDS | 8 (9) |
| <5% blasts | 4 |
| ≥5% blasts | 4 |
| CML | 3 (3) |
| Chronic phase | 2 |
| Accelerated phase | 1 |
| MPD | 3 (3) |
| <5% blasts | 2 |
| ≥5% blasts | 1 |
| NHL | 14 (16) |
| Large cell B cell | 2 (2) |
| CR | 1 |
| PR | 1 |
| Low-grade B-cell | 3 (3) |
| CR | 2 |
| PR | 1 |
| T cell | 9 (10) |
| CR | 4 |
| PR | 4 |
| Progressive disease | 1 |
| Blastic plasmacytoid dendritic cell neoplasm | 1 (1) |
| CR | 1 |
| HCT-CI, n (%) | |
| 0 | 18 (20) |
| 1-2 | 40 (44) |
| 3-4 | 26 (29) |
| 5-8 | 6 (7) |
| Median (range) | 2 (0-8) |
| rDRI, n (%) | |
| Low | 6 (7) |
| Intermediate | 62 (69) |
| High | 21 (23) |
| Very high | 1 (1) |
| Graft characteristics (n = 180 units)* | |
| Infused TNC dose, median (range), × 107/kg per unit | 2.5 (1.0-7.4) |
| Infused viable CD34+ dose, median (range), × 105/kg per unit | 1.3 (0.2-8.3) |
| Unit recipient HLA- A, -B antigen, -DR allele match, n (%) | |
| 4/6 | 162 (90) |
| 5/6 | 16 (9) |
| 6/6 | 2 (1) |
| Unit recipient 8-allele HLA-match, n (%) | |
| 3-4/8 | 80 (44) |
| 5/8 | 76 (42) |
| 6-7/8 | 24 (13) |
| Median (range) | 5/8 (3-7/8) |
dCB grafts were supplemented with haplo-identical mobilized peripheral blood CD34+ cells in 43 (48%) patients.18 Haplo-identical donors (median age, 30 y) were siblings (n = 15), children (n = 20), parents (n = 4), or other family members (n = 4).